Concordance of Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced Ovarian Cancer

Simple Summary In women affected by advanced ovarian cancer, complete cytoreductive surgery is of paramount important to achieve the best oncological outcomes. In this study, we compared radiologic, laparoscopic, and laparotomic scoring assessments to identify the best strategy to predict the achievement of complete cytoreductive surgery, both in upfront surgery and in neoadjuvant chemotherapy and subsequent surgery. We found that laparoscopic score assessment had a high accuracy for optimal cytoreduction in women affected by advanced ovarian cancer who need to undergo surgical management. Abstract Objective: To identify the best method among the radiologic, laparoscopic and laparotomic scoring assessment to predict the outcomes of cytoreductive surgery in patients with advanced ovarian cancer (AOC). Methods: Patients with AOC who underwent pre-operative computed tomography (CT) scan, laparoscopic evaluation, and cytoreductive surgery between August 2016 and February 2021 were retrospectively reviewed. Predictive Index (PI) score and Peritoneal Cancer Index (PCI) scores were used to estimate the tumor load and predict the residual disease in the primary debulking surgery (PDS) and interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) groups. Concordance percentages were calculated between the two scores. Results: Among 100 eligible patients, 69 underwent PDS, and 31 underwent NACT and IDS. Complete cytoreduction was achieved in 72.5% of patients in the PDS group and 77.4% in the IDS. In patients undergoing PDS, the laparoscopic PI and the laparotomic PCI had the best accuracies for complete cytoreduction (R0) [area under the curve (AUC) = 0.78 and AUC = 0.83, respectively]. In the IDS group, the laparotomic PI (AUC = 0.75) and the laparoscopic PCI (AUC= 0.87) were associated with the best accuracy in R0 prediction. Furthermore, radiological assessment, through PI and PCI, was associated with the worst accuracy in either PDS or IDS group (PI in PDS: AUC = 0.64; PCI in PDS: AUC = 0.64; PI in IDS: AUC = 0.46; PCI in IDS: AUC = 0.47). Conclusion: The laparoscopic score assessment had high accuracy for optimal cytoreduction in AOC patients undergoing PDS or IDS. Integrating diagnostic laparoscopy in the decision-making algorithm to accurately triage AOC patients to different treatment strategies seems necessary.

[1]  P. Van Trappen,et al.  Robotic surgery in early and advanced ovarian cancer: Case selection for surgical staging and interval debulking surgery. , 2022, European journal of obstetrics, gynecology, and reproductive biology.

[2]  I. Zapardiel,et al.  18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) predictive score for complete resection in primary cytoreductive surgery , 2022, International Journal of Gynecological Cancer.

[3]  E. Goode,et al.  Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer. , 2022, Gynecologic oncology.

[4]  J. Magrina,et al.  Does MIS Play a Role in the Treatment of Advanced Ovarian Cancer? , 2022, Cancers.

[5]  P. Cybulska,et al.  Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer. , 2022, Gynecologic oncology.

[6]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[7]  J. Berek,et al.  Cancer of the ovary, fallopian tube, and peritoneum: 2021 update , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[8]  S. Kehoe,et al.  Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. , 2021, The Cochrane database of systematic reviews.

[9]  Kyunghwa Han,et al.  CT-Based Fagotti Scoring System for Non-Invasive Prediction of Cytoreduction Surgery Outcome in Patients with Advanced Ovarian Cancer , 2021, Korean Journal of Radiology.

[10]  K. Stålberg,et al.  Validation of 18F-FDG PET/MRI and diffusion-weighted MRI for estimating the extent of peritoneal carcinomatosis in ovarian and endometrial cancer -a pilot study , 2021, Cancer Imaging.

[11]  J. Mountz,et al.  Diagnostic Value of FDG PET/MRI in Females With Pelvic Malignancy—A Systematic Review of the Literature , 2020, Frontiers in Oncology.

[12]  R. Raffaelli,et al.  Secondary and tertiary ovarian cancer recurrence: what is the best management? , 2020, Gland surgery.

[13]  S. Rizzo,et al.  Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study. , 2019, European journal of radiology.

[14]  D. Timmerman,et al.  ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  G. Scambia,et al.  The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy , 2019, International Journal of Gynecologic Cancer.

[16]  B. Chiofalo,et al.  Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis , 2019, Minerva medica.

[17]  A. Sood,et al.  Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. , 2018, Gynecologic oncology.

[18]  J. Escrig,et al.  Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index , 2018, World Journal of Surgical Oncology.

[19]  G. Bogani,et al.  A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses , 2018, Journal of gynecologic oncology.

[20]  G. Scambia,et al.  Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. , 2016, American journal of obstetrics and gynecology.

[21]  G. Scambia,et al.  Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. , 2015, Gynecologic oncology.

[22]  A. Sood,et al.  Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. , 2015, Gynecologic oncology.

[23]  R. Granese,et al.  Cytogenetic analysis of epithelial ovarian cancer's stem cells: an overview on new diagnostic and therapeutic perspectives. , 2015, European journal of gynaecological oncology.

[24]  Douglas G Altman,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.

[25]  H. Hricak,et al.  A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. , 2014, Gynecologic oncology.

[26]  G. Scambia,et al.  Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. , 2013, Gynecologic oncology.

[27]  R. Rouzier,et al.  External validation of a laparoscopic-based score to evaluate resectability for patients with advanced ovarian cancer undergoing interval debulking surgery. , 2011, Anticancer research.

[28]  E. Sala,et al.  ESUR guidelines: ovarian cancer staging and follow-up , 2010, European Radiology.

[29]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[30]  G. Scambia,et al.  Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? , 2010, Gynecologic oncology.

[31]  G. Scambia,et al.  Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial , 2009, British Journal of Cancer.

[32]  D. Jung,et al.  Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer , 2009, European Radiology.

[33]  R. Rouzier,et al.  External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. , 2008, Gynecologic oncology.

[34]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.

[35]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[36]  D. Chi,et al.  A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. , 2007, Gynecologic oncology.

[37]  B. Karlan,et al.  Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Scambia,et al.  A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study , 2006, Annals of Surgical Oncology.

[39]  W. Cliby,et al.  Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer , 2006, Obstetrics and gynecology.

[40]  K. Brandt,et al.  The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma , 2004, Cancer.

[41]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  ESUR BOARD,et al.  European Society of Urogenital Radiology (ESUR) , 2001, European Radiology.

[43]  P. Sugarbaker,et al.  Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. , 1996, Cancer treatment and research.

[44]  K. Jablonski,et al.  Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy , 1995, Annals of surgery.

[45]  H. Hansen,et al.  Performance status assessment in cancer patients. An inter-observer variability study. , 1993, British Journal of Cancer.

[46]  C. Conill,et al.  Performance status assessment in cancer patients , 1990, Cancer.